We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.
Waltham, United States
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
1 Product
Specialised areas
Biotechnology
Avilar Therapeutics offers a wide range of products and services
Product
ATAC Platform - Avilar Therapeutics
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Avilar Therapeutics operates in 1 country around the world
Get an overview of the locations of Avilar Therapeutics
Location
Country
State
City
Headquarter
United States
Massachusetts
Waltham
Some frequent questions that have been asked about Avilar Therapeutics
Where is Avilar Therapeutics located?
The company headquarter of Avilar Therapeutics is located in Waltham, Massachusetts, United States. It's worth noting, that the company may have more locations
How many employees does Avilar Therapeutics approximately have?
As of the latest available information Avilar Therapeutics has around 11-50 employees worldwide.
In which industries does Avilar Therapeutics mainly work?
The company Avilar Therapeutics has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Avilar Therapeutics
Orum Therapeutics
Kazan, Russia
11-50 Employees
2016
We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.
PAQ Therapeutics
Cambridge, United States
1-10 Employees
2020
We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.
16250 - 1st TPD Europe 2020
London, United Kingdom
1-10 Employees
-
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
Aptadegrad
San Cibrao das Viñas, Spain
1-10 Employees
2022
Invest in Aptadegrad, a great opportunity to create value with rapid development of new compounds. Non-biological manufacturing of both the chemical degraders and the warheads avoids high costs and greatly reduces logistics constraints. We would be delighted to show you the advantages and benefits that Aptadegrad can provide you.
Atgc Inc
Ann Arbor, United States
1-10 Employees
2015
Our mission is to discover the best-in-class therapeutic biologics through the novel animals and technology platforms. Our mission is to discover the best-in-class therapeutics through the novel platforms. The company is dedicated to the development of novel transgenic rabbits as discovery platforms and bioreactors to produce therapeutic biologics such as monoclonal antibodies. ATGC also provides services to the biomedical community using our proprietary technology platforms and unique animals. ATGC also strives to serve the biomedical community with products and technologies using our unique platforms.
Lycia Therapeutics
San Diego, United States
11-50 Employees
2019
To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.